The global market for Nucleic Acid-based Drugs was valued at US$ 14636 million in the year 2024 and is projected to reach a revised size of US$ 21728 million by 2031, growing at a CAGR of 7.5% during the forecast period.

Nucleic Acid-based Drugs Market

Nucleic acid-based drugs are a new generation of biologics that use nucleic acids—including but not limited to antisense oligonucleotides (ASOs), siRNA, mRNA, aptamers, and gene-editing vectors—as active ingredients to modulate gene expression or directly replace/modify genetic information for therapeutic effect. Unlike conventional small molecules or protein therapeutics, nucleic acid drugs can intervene at the molecular root of disease with high target specificity and sequence designability, enabling access to historically “undruggable” targets. In recent years, advances in mRNA platforms, modified nucleotides, and delivery systems (such as lipid nanoparticles) have significantly accelerated clinical translation and industrial-scale manufacturing, moving the field rapidly from research-driven innovation toward commercialization and making it a core disruptive track in the pharmaceutical industry.

Opportunities in the nucleic acid drug sector stem from the convergence of technology and policy: platform advancements in mRNA, chemical nucleotide modification, and LNP delivery have shortened development timelines and expanded potential indications; regulatory acceptance and public-health prioritization have integrated nucleic acid products into national biopharmaceutical strategies, generating policy and procurement support. Meanwhile, sustained capital inflows and the commercial success of approved nucleic acid therapies are building an end-to-end ecosystem—from upstream materials and CMC to downstream distribution—creating immediate market expansion opportunities for companies with robust platforms and regulatory experience.

Despite promising prospects, commercialization faces material risks: delivery efficiency, tissue-specific targeting, and long-term safety require extensive clinical validation; upstream supply concentration and quality consistency of critical materials (modified nucleotides, lipid components, enzymes) challenge manufacturing resilience; regulatory heterogeneity and reimbursement/price uncertainties can slow adoption. Intensifying competition further means that without differentiated platforms and reliable manufacturing capability, new entrants will struggle to secure sustainable market positions.

Downstream demand is expanding from research and early clinical use to broader therapeutic and prophylactic applications. Clinically, rare diseases, genetic/metabolic disorders, oncology, and infectious disease vaccines drive strong demand for nucleic acid therapeutics; market-wise, healthcare institutions, specialty treatment centers, and commercial distribution networks are scaling to support chronic administration and cold-chain logistics; payer and buyer behavior is shifting from pilot or grant-driven uptake to value-driven procurement, with an increased focus on real-world effectiveness, cost-effectiveness, and accessibility—factors that will amplify demand for standardized, scalable nucleic acid formulations.

Key upstream inputs for nucleic acid drugs include synthesized and modified nucleotides, carrier materials (e.g., LNP components), high-purity enzymes and reagents, and GMP-grade consumables and equipment. As mRNA and siRNA products move to large-scale production, upstream requirements for quality, traceability, and batch consistency intensify, driving higher supplier concentration and the need for long-term supply agreements. Geographic dependencies and geopolitical risks are incentivizing companies to pursue localization and strategic inventory to ensure supply continuity and manufacturing resilience.The average gross profit margin of this product is 85%.

This report aims to provide a comprehensive presentation of the global market for Nucleic Acid-based Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acid-based Drugs.

The Nucleic Acid-based Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Nucleic Acid-based Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Nucleic Acid-based Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Nucleic Acid-based Drugs Market Report

Report Metric	Details
Report Name	Nucleic Acid-based Drugs Market
Accounted market size in year	US$ 14636 million
Forecasted market size in 2031	US$ 21728 million
CAGR	7.5%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Antisense Oligonucleotides (ASO) siRNA mRNA Other
Segment by Application	Neuromuscular Diseases hATTR COVID-19 Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, Jazz Pharmaceuticals, Novo Nordisk, AstraZeneca, Astellas Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid-based Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Nucleic Acid-based Drugs Market growing?

Ans: The Nucleic Acid-based Drugs Market witnessing a CAGR of 7.5% during the forecast period 2025-2031.

What is the Nucleic Acid-based Drugs Market size in 2031?

Ans: The Nucleic Acid-based Drugs Market size in 2031 will be US$ 21728 million.

Who are the main players in the Nucleic Acid-based Drugs Market report?

Ans: The main players in the Nucleic Acid-based Drugs Market are Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, Jazz Pharmaceuticals, Novo Nordisk, AstraZeneca, Astellas Pharma

What are the Application segmentation covered in the Nucleic Acid-based Drugs Market report?

Ans: The Applications covered in the Nucleic Acid-based Drugs Market report are Neuromuscular Diseases, hATTR, COVID-19, Other

What are the Type segmentation covered in the Nucleic Acid-based Drugs Market report?

Ans: The Types covered in the Nucleic Acid-based Drugs Market report are Antisense Oligonucleotides (ASO), siRNA, mRNA, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Nucleic Acid-based Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Antisense Oligonucleotides (ASO)

1.2.3 siRNA

1.2.4 mRNA

1.2.5 Other

1.3 Market by Application

1.3.1 Global Nucleic Acid-based Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Neuromuscular Diseases

1.3.3 hATTR

1.3.4 COVID-19

1.3.5 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Nucleic Acid-based Drugs Market Perspective (2020-2031)

2.2 Global Nucleic Acid-based Drugs Growth Trends by Region

2.2.1 Global Nucleic Acid-based Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Nucleic Acid-based Drugs Historic Market Size by Region (2020-2025)

2.2.3 Nucleic Acid-based Drugs Forecasted Market Size by Region (2026-2031)

2.3 Nucleic Acid-based Drugs Market Dynamics

2.3.1 Nucleic Acid-based Drugs Industry Trends

2.3.2 Nucleic Acid-based Drugs Market Drivers

2.3.3 Nucleic Acid-based Drugs Market Challenges

2.3.4 Nucleic Acid-based Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Nucleic Acid-based Drugs Players by Revenue

3.1.1 Global Top Nucleic Acid-based Drugs Players by Revenue (2020-2025)

3.1.2 Global Nucleic Acid-based Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Top Nucleic Acid-based Drugs Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Nucleic Acid-based Drugs Revenue

3.4 Global Nucleic Acid-based Drugs Market Concentration Ratio

3.4.1 Global Nucleic Acid-based Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid-based Drugs Revenue in 2024

3.5 Global Key Players of Nucleic Acid-based Drugs Head office and Area Served

3.6 Global Key Players of Nucleic Acid-based Drugs, Product and Application

3.7 Global Key Players of Nucleic Acid-based Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Nucleic Acid-based Drugs Breakdown Data by Type

4.1 Global Nucleic Acid-based Drugs Historic Market Size by Type (2020-2025)

4.2 Global Nucleic Acid-based Drugs Forecasted Market Size by Type (2026-2031)

5 Nucleic Acid-based Drugs Breakdown Data by Application

5.1 Global Nucleic Acid-based Drugs Historic Market Size by Application (2020-2025)

5.2 Global Nucleic Acid-based Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Nucleic Acid-based Drugs Market Size (2020-2031)

6.2 North America Nucleic Acid-based Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Nucleic Acid-based Drugs Market Size by Country (2020-2025)

6.4 North America Nucleic Acid-based Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Nucleic Acid-based Drugs Market Size (2020-2031)

7.2 Europe Nucleic Acid-based Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Nucleic Acid-based Drugs Market Size by Country (2020-2025)

7.4 Europe Nucleic Acid-based Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Nucleic Acid-based Drugs Market Size (2020-2031)

8.2 Asia-Pacific Nucleic Acid-based Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Nucleic Acid-based Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Nucleic Acid-based Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Nucleic Acid-based Drugs Market Size (2020-2031)

9.2 Latin America Nucleic Acid-based Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Nucleic Acid-based Drugs Market Size by Country (2020-2025)

9.4 Latin America Nucleic Acid-based Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Nucleic Acid-based Drugs Market Size (2020-2031)

10.2 Middle East & Africa Nucleic Acid-based Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Nucleic Acid-based Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Nucleic Acid-based Drugs Market Size by Country (2026-2031)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Sarepta Therapeutics

11.1.1 Sarepta Therapeutics Company Details

11.1.2 Sarepta Therapeutics Business Overview

11.1.3 Sarepta Therapeutics Nucleic Acid-based Drugs Introduction

11.1.4 Sarepta Therapeutics Revenue in Nucleic Acid-based Drugs Business (2020-2025)

11.1.5 Sarepta Therapeutics Recent Development

11.2 Ionis Pharmaceuticals

11.2.1 Ionis Pharmaceuticals Company Details

11.2.2 Ionis Pharmaceuticals Business Overview

11.2.3 Ionis Pharmaceuticals Nucleic Acid-based Drugs Introduction

11.2.4 Ionis Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2020-2025)

11.2.5 Ionis Pharmaceuticals Recent Development

11.3 Alnylam

11.3.1 Alnylam Company Details

11.3.2 Alnylam Business Overview

11.3.3 Alnylam Nucleic Acid-based Drugs Introduction

11.3.4 Alnylam Revenue in Nucleic Acid-based Drugs Business (2020-2025)

11.3.5 Alnylam Recent Development

11.4 Biogen

11.4.1 Biogen Company Details

11.4.2 Biogen Business Overview

11.4.3 Biogen Nucleic Acid-based Drugs Introduction

11.4.4 Biogen Revenue in Nucleic Acid-based Drugs Business (2020-2025)

11.4.5 Biogen Recent Development

11.5 Nippon Shinyaku

11.5.1 Nippon Shinyaku Company Details

11.5.2 Nippon Shinyaku Business Overview

11.5.3 Nippon Shinyaku Nucleic Acid-based Drugs Introduction

11.5.4 Nippon Shinyaku Revenue in Nucleic Acid-based Drugs Business (2020-2025)

11.5.5 Nippon Shinyaku Recent Development

11.6 Sobi

11.6.1 Sobi Company Details

11.6.2 Sobi Business Overview

11.6.3 Sobi Nucleic Acid-based Drugs Introduction

11.6.4 Sobi Revenue in Nucleic Acid-based Drugs Business (2020-2025)

11.6.5 Sobi Recent Development

11.7 Novartis

11.7.1 Novartis Company Details

11.7.2 Novartis Business Overview

11.7.3 Novartis Nucleic Acid-based Drugs Introduction

11.7.4 Novartis Revenue in Nucleic Acid-based Drugs Business (2020-2025)

11.7.5 Novartis Recent Development

11.8 BioNTech

11.8.1 BioNTech Company Details

11.8.2 BioNTech Business Overview

11.8.3 BioNTech Nucleic Acid-based Drugs Introduction

11.8.4 BioNTech Revenue in Nucleic Acid-based Drugs Business (2020-2025)

11.8.5 BioNTech Recent Development

11.9 Pfizer

11.9.1 Pfizer Company Details

11.9.2 Pfizer Business Overview

11.9.3 Pfizer Nucleic Acid-based Drugs Introduction

11.9.4 Pfizer Revenue in Nucleic Acid-based Drugs Business (2020-2025)

11.9.5 Pfizer Recent Development

11.10 Moderna Therapeutics

11.10.1 Moderna Therapeutics Company Details

11.10.2 Moderna Therapeutics Business Overview

11.10.3 Moderna Therapeutics Nucleic Acid-based Drugs Introduction

11.10.4 Moderna Therapeutics Revenue in Nucleic Acid-based Drugs Business (2020-2025)

11.10.5 Moderna Therapeutics Recent Development

11.11 Jazz Pharmaceuticals

11.11.1 Jazz Pharmaceuticals Company Details

11.11.2 Jazz Pharmaceuticals Business Overview

11.11.3 Jazz Pharmaceuticals Nucleic Acid-based Drugs Introduction

11.11.4 Jazz Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2020-2025)

11.11.5 Jazz Pharmaceuticals Recent Development

11.12 Novo Nordisk

11.12.1 Novo Nordisk Company Details

11.12.2 Novo Nordisk Business Overview

11.12.3 Novo Nordisk Nucleic Acid-based Drugs Introduction

11.12.4 Novo Nordisk Revenue in Nucleic Acid-based Drugs Business (2020-2025)

11.12.5 Novo Nordisk Recent Development

11.13 AstraZeneca

11.13.1 AstraZeneca Company Details

11.13.2 AstraZeneca Business Overview

11.13.3 AstraZeneca Nucleic Acid-based Drugs Introduction

11.13.4 AstraZeneca Revenue in Nucleic Acid-based Drugs Business (2020-2025)

11.13.5 AstraZeneca Recent Development

11.14 Astellas Pharma

11.14.1 Astellas Pharma Company Details

11.14.2 Astellas Pharma Business Overview

11.14.3 Astellas Pharma Nucleic Acid-based Drugs Introduction

11.14.4 Astellas Pharma Revenue in Nucleic Acid-based Drugs Business (2020-2025)

11.14.5 Astellas Pharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Ionis Pharmaceuticals

Sarepta Therapeutics

Nippon Shinyaku

BioNTech

Moderna Therapeutics

List of Tables

Table 1. Global Nucleic Acid-based Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Antisense Oligonucleotides (ASO)

Table 3. Key Players of siRNA

Table 4. Key Players of mRNA

Table 5. Key Players of Other

Table 6. Global Nucleic Acid-based Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Nucleic Acid-based Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Nucleic Acid-based Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Nucleic Acid-based Drugs Market Share by Region (2020-2025)

Table 10. Global Nucleic Acid-based Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Nucleic Acid-based Drugs Market Share by Region (2026-2031)

Table 12. Nucleic Acid-based Drugs Market Trends

Table 13. Nucleic Acid-based Drugs Market Drivers

Table 14. Nucleic Acid-based Drugs Market Challenges

Table 15. Nucleic Acid-based Drugs Market Restraints

Table 16. Global Nucleic Acid-based Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Nucleic Acid-based Drugs Market Share by Players (2020-2025)

Table 18. Global Top Nucleic Acid-based Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid-based Drugs as of 2024)

Table 19. Ranking of Global Top Nucleic Acid-based Drugs Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Nucleic Acid-based Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Nucleic Acid-based Drugs, Headquarters and Area Served

Table 22. Global Key Players of Nucleic Acid-based Drugs, Product and Application

Table 23. Global Key Players of Nucleic Acid-based Drugs, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Nucleic Acid-based Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Nucleic Acid-based Drugs Revenue Market Share by Type (2020-2025)

Table 27. Global Nucleic Acid-based Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Nucleic Acid-based Drugs Revenue Market Share by Type (2026-2031)

Table 29. Global Nucleic Acid-based Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Nucleic Acid-based Drugs Revenue Market Share by Application (2020-2025)

Table 31. Global Nucleic Acid-based Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Nucleic Acid-based Drugs Revenue Market Share by Application (2026-2031)

Table 33. North America Nucleic Acid-based Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Nucleic Acid-based Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Nucleic Acid-based Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Nucleic Acid-based Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Nucleic Acid-based Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Nucleic Acid-based Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Nucleic Acid-based Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Nucleic Acid-based Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Nucleic Acid-based Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Nucleic Acid-based Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Nucleic Acid-based Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Nucleic Acid-based Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Nucleic Acid-based Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Nucleic Acid-based Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Nucleic Acid-based Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 48. Sarepta Therapeutics Company Details

Table 49. Sarepta Therapeutics Business Overview

Table 50. Sarepta Therapeutics Nucleic Acid-based Drugs Product

Table 51. Sarepta Therapeutics Revenue in Nucleic Acid-based Drugs Business (2020-2025) & (US$ Million)

Table 52. Sarepta Therapeutics Recent Development

Table 53. Ionis Pharmaceuticals Company Details

Table 54. Ionis Pharmaceuticals Business Overview

Table 55. Ionis Pharmaceuticals Nucleic Acid-based Drugs Product

Table 56. Ionis Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2020-2025) & (US$ Million)

Table 57. Ionis Pharmaceuticals Recent Development

Table 58. Alnylam Company Details

Table 59. Alnylam Business Overview

Table 60. Alnylam Nucleic Acid-based Drugs Product

Table 61. Alnylam Revenue in Nucleic Acid-based Drugs Business (2020-2025) & (US$ Million)

Table 62. Alnylam Recent Development

Table 63. Biogen Company Details

Table 64. Biogen Business Overview

Table 65. Biogen Nucleic Acid-based Drugs Product

Table 66. Biogen Revenue in Nucleic Acid-based Drugs Business (2020-2025) & (US$ Million)

Table 67. Biogen Recent Development

Table 68. Nippon Shinyaku Company Details

Table 69. Nippon Shinyaku Business Overview

Table 70. Nippon Shinyaku Nucleic Acid-based Drugs Product

Table 71. Nippon Shinyaku Revenue in Nucleic Acid-based Drugs Business (2020-2025) & (US$ Million)

Table 72. Nippon Shinyaku Recent Development

Table 73. Sobi Company Details

Table 74. Sobi Business Overview

Table 75. Sobi Nucleic Acid-based Drugs Product

Table 76. Sobi Revenue in Nucleic Acid-based Drugs Business (2020-2025) & (US$ Million)

Table 77. Sobi Recent Development

Table 78. Novartis Company Details

Table 79. Novartis Business Overview

Table 80. Novartis Nucleic Acid-based Drugs Product

Table 81. Novartis Revenue in Nucleic Acid-based Drugs Business (2020-2025) & (US$ Million)

Table 82. Novartis Recent Development

Table 83. BioNTech Company Details

Table 84. BioNTech Business Overview

Table 85. BioNTech Nucleic Acid-based Drugs Product

Table 86. BioNTech Revenue in Nucleic Acid-based Drugs Business (2020-2025) & (US$ Million)

Table 87. BioNTech Recent Development

Table 88. Pfizer Company Details

Table 89. Pfizer Business Overview

Table 90. Pfizer Nucleic Acid-based Drugs Product

Table 91. Pfizer Revenue in Nucleic Acid-based Drugs Business (2020-2025) & (US$ Million)

Table 92. Pfizer Recent Development

Table 93. Moderna Therapeutics Company Details

Table 94. Moderna Therapeutics Business Overview

Table 95. Moderna Therapeutics Nucleic Acid-based Drugs Product

Table 96. Moderna Therapeutics Revenue in Nucleic Acid-based Drugs Business (2020-2025) & (US$ Million)

Table 97. Moderna Therapeutics Recent Development

Table 98. Jazz Pharmaceuticals Company Details

Table 99. Jazz Pharmaceuticals Business Overview

Table 100. Jazz Pharmaceuticals Nucleic Acid-based Drugs Product

Table 101. Jazz Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2020-2025) & (US$ Million)

Table 102. Jazz Pharmaceuticals Recent Development

Table 103. Novo Nordisk Company Details

Table 104. Novo Nordisk Business Overview

Table 105. Novo Nordisk Nucleic Acid-based Drugs Product

Table 106. Novo Nordisk Revenue in Nucleic Acid-based Drugs Business (2020-2025) & (US$ Million)

Table 107. Novo Nordisk Recent Development

Table 108. AstraZeneca Company Details

Table 109. AstraZeneca Business Overview

Table 110. AstraZeneca Nucleic Acid-based Drugs Product

Table 111. AstraZeneca Revenue in Nucleic Acid-based Drugs Business (2020-2025) & (US$ Million)

Table 112. AstraZeneca Recent Development

Table 113. Astellas Pharma Company Details

Table 114. Astellas Pharma Business Overview

Table 115. Astellas Pharma Nucleic Acid-based Drugs Product

Table 116. Astellas Pharma Revenue in Nucleic Acid-based Drugs Business (2020-2025) & (US$ Million)

Table 117. Astellas Pharma Recent Development

Table 118. Research Programs/Design for This Report

Table 119. Key Data Information from Secondary Sources

Table 120. Key Data Information from Primary Sources

Table 121. Authors List of This Report

List of Figures

Figure 1. Nucleic Acid-based Drugs Picture

Figure 2. Global Nucleic Acid-based Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Nucleic Acid-based Drugs Market Share by Type: 2024 VS 2031

Figure 4. Antisense Oligonucleotides (ASO) Features

Figure 5. siRNA Features

Figure 6. mRNA Features

Figure 7. Other Features

Figure 8. Global Nucleic Acid-based Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Nucleic Acid-based Drugs Market Share by Application: 2024 VS 2031

Figure 10. Neuromuscular Diseases Case Studies

Figure 11. hATTR Case Studies

Figure 12. COVID-19 Case Studies

Figure 13. Other Case Studies

Figure 14. Nucleic Acid-based Drugs Report Years Considered

Figure 15. Global Nucleic Acid-based Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 16. Global Nucleic Acid-based Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Nucleic Acid-based Drugs Market Share by Region: 2024 VS 2031

Figure 18. Global Nucleic Acid-based Drugs Market Share by Players in 2024

Figure 19. Global Nucleic Acid-based Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 20. The Top 10 and 5 Players Market Share by Nucleic Acid-based Drugs Revenue in 2024

Figure 21. North America Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. North America Nucleic Acid-based Drugs Market Share by Country (2020-2031)

Figure 23. United States Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Canada Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Nucleic Acid-based Drugs Market Share by Country (2020-2031)

Figure 27. Germany Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. France Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. U.K. Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Italy Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Russia Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Ireland Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific Nucleic Acid-based Drugs Market Share by Region (2020-2031)

Figure 35. China Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Japan Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. South Korea Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Southeast Asia Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. India Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Australia & New Zealand Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America Nucleic Acid-based Drugs Market Share by Country (2020-2031)

Figure 43. Mexico Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Brazil Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa Nucleic Acid-based Drugs Market Share by Country (2020-2031)

Figure 47. Israel Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Saudi Arabia Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. UAE Nucleic Acid-based Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Sarepta Therapeutics Revenue Growth Rate in Nucleic Acid-based Drugs Business (2020-2025)

Figure 51. Ionis Pharmaceuticals Revenue Growth Rate in Nucleic Acid-based Drugs Business (2020-2025)

Figure 52. Alnylam Revenue Growth Rate in Nucleic Acid-based Drugs Business (2020-2025)

Figure 53. Biogen Revenue Growth Rate in Nucleic Acid-based Drugs Business (2020-2025)

Figure 54. Nippon Shinyaku Revenue Growth Rate in Nucleic Acid-based Drugs Business (2020-2025)

Figure 55. Sobi Revenue Growth Rate in Nucleic Acid-based Drugs Business (2020-2025)

Figure 56. Novartis Revenue Growth Rate in Nucleic Acid-based Drugs Business (2020-2025)

Figure 57. BioNTech Revenue Growth Rate in Nucleic Acid-based Drugs Business (2020-2025)

Figure 58. Pfizer Revenue Growth Rate in Nucleic Acid-based Drugs Business (2020-2025)

Figure 59. Moderna Therapeutics Revenue Growth Rate in Nucleic Acid-based Drugs Business (2020-2025)

Figure 60. Jazz Pharmaceuticals Revenue Growth Rate in Nucleic Acid-based Drugs Business (2020-2025)

Figure 61. Novo Nordisk Revenue Growth Rate in Nucleic Acid-based Drugs Business (2020-2025)

Figure 62. AstraZeneca Revenue Growth Rate in Nucleic Acid-based Drugs Business (2020-2025)

Figure 63. Astellas Pharma Revenue Growth Rate in Nucleic Acid-based Drugs Business (2020-2025)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global RNA Medicine Market Research Report 2024

RNA Based Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Genome Based Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global siRNA Drugs Market Research Report 2024

Global Still s Disease Treatment Market Research Report 2025

Global Nano Pharmaceutical Market Research Report 2024

Global Diagnostic Guidewire Market Research Report 2024

Global Autoimmune Diseases Treatment Market Research Report 2024

Global Drugs of Abuse Testing Market Research Report 2024

Global Ant Killer Market Research Report 2024

Global Anti infectious Disease Drugs Market Research Report 2025

Global RNA Targeted Small Molecule Drugs Market Research Report 2025

Systemic Infection Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Influenza Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Ophthalmology AI assisted Diagnosis Software Market Research Report 2024

Global Combination Therapy Drug Market Research Report 2025

Global Coding and Marking for Pharmaceuticals and Consumer Products Market Research Report 2024

Global Chinese Medicine Market Research Report 2024

Prescription Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Pharmacy Chatbot Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10T20319

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Inline Pharmaceutical Packaging Leak Detection System Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-6Q20319

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Radiological Marker Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-35Z19949

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Pharmaceutical Biomanufacturing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-26E19785

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions